Lite Strategy LITS
NASDAQ LITS
$0.99 +0.05 (+4.91%)
At close: Aug 21, 2026 · 4:00 PM EDT

Lite Strategy (LITS) Cash from Financing Activities (2011 - 2026)

Lite Strategy (LITS) posted quarterly Cash from Financing Activities of -$1.8 million for Q1 2026, down 35940.0% quarter-over-quarter from $5000.0 in Q4 2025.

Lite Strategy (LITS) Cash from Financing Activities (2011 - 2026) Analysis & Trends

Lite Strategy's Cash from Financing Activities history runs 16 years deep, the most recent figure standing at -$1.8 million for Q1 2026.

  • In Q1 2026, Cash from Financing Activities changed N/A year-over-year to -$1.8 million; the TTM figure through Mar 2026 stood at $94.8 million (up 45687.98% YoY), while the FY2024 annual figure was -$11.9 million, down 29570.0% from the prior year.
  • Cash from Financing Activities for Q1 2026 stood at -$1.8 million, down from $5000.0 in the prior quarter.
  • The five-year high for Cash from Financing Activities was $96.6 million in Q3 2025, with the low at -$11.7 million in Q4 2023.
  • The 5-year median for Cash from Financing Activities is -$17500.0 (2022), against an average of $10.4 million.
  • Peak annual rise in Cash from Financing Activities reached 185.71% in 2022, while the deepest fall reached 70.15% in 2022.
  • Lite Strategy's Cash from Financing Activities stood at -$40000.0 in 2022, then tumbled by 29050.0% to -$11.7 million in 2023, then jumped by 98.22% to -$208000.0 in 2024, then soared by 102.4% to $5000.0 in 2025, then tumbled by 35940.0% to -$1.8 million in 2026.
  • Business Quant data shows LITS's Cash from Financing Activities at -$1.8 million in Q1 2026, $5000.0 in Q4 2025, and $96.6 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Financing Activities (Qtr)
1 Vertex Pharmaceuticals 139.13 Bn 131.28 Bn 2.84 Bn -426.70 Mn
2 Regeneron Pharmaceuticals 85.77 Bn 77.77 Bn 3.93 Bn -1.22 Bn
3 Argenx Se 64.64 Bn 59.46 Bn 1.37 Bn -
4 Moderna 58.29 Bn 53.16 Bn 52.00 Mn 14.00 Mn
5 BeOne Medicines 41.92 Bn 36.82 Bn 1.53 Bn -6.05 Mn
6 Alnylam Pharmaceuticals 31.58 Bn 28.28 Bn 992.69 Mn 36.24 Mn
7 BioNTech SE 28.12 Bn 9.73 Bn 668.28 Mn -16.65 Mn
8 Insmed 27.39 Bn 26.22 Bn 358.27 Mn 27.18 Mn
9 Royalty Pharma 27.27 Bn 26.43 Bn - -273.15 Mn
10 Lite Strategy 35.71 Mn 28.17 Mn - -1.79 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -1.79 Mn
Mar 31, 2026 -1.79 Mn
Dec 31, 2025 5,000.00
Dec 31, 2025 5,000.00
Sep 30, 2025 96.61 Mn
Sep 30, 2025 96.61 Mn
Jun 30, 2024 -208,000.00
Jun 30, 2024 -208,000.00
Dec 31, 2023 -11.66 Mn
Dec 31, 2023 -11.66 Mn
Sep 30, 2022 -40,000.00
Sep 30, 2022 -40,000.00
Jun 30, 2022 20,000.00
Jun 30, 2022 20,000.00
Mar 31, 2022 360,000.00
Mar 31, 2022 360,000.00
Dec 31, 2021 48.87 Mn
Dec 31, 2021 48.87 Mn
Sep 30, 2021 -194,000.00
Sep 30, 2021 -194,000.00